# Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

> **NCT01011439** · PHASE2 · TERMINATED · sponsor: **Tiziana Life Sciences LTD** · enrollment: 72 (actual)

## Conditions studied

- Thymic Carcinoma

## Interventions

- **DRUG:** Milciclib Maleate

## Key facts

- **NCT ID:** NCT01011439
- **Lead sponsor:** Tiziana Life Sciences LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02-22
- **Primary completion:** 2017-05-31
- **Final completion:** 2018-12-17
- **Target enrollment:** 72 (ACTUAL)
- **Why stopped:** For the 2 last patients still on treated nominal therapeutic use of the Milciclib was approved at INT Milano.
- **Last updated:** 2019-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01011439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01011439, "Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT01011439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*